For instance, our group has used the Kras; Pten mouse model, in which tumours have high levels of mTOR (mammalian target of rapamycin) signalling, to test the efficacy of an mTOR inhibitor (Morran et al., 2014). This evidence concerns the gene MTOR and neoplasm.